BioStock: Curasight CEO: “Working on accelerated plan for uTREAT”

Looking back at the third quarter, it’s clear that Curasight is keeping the momentum in the development. Among other things, the much-anticipated phase II results in brain cancer were presented at the World Molecular Imaging Congress. The company now look forward to more results, while filing applications for further studies with both uTRACE and uTREAT. BioStock contacted Curasight’s CEO Ulrich Krasilnikoff to learn more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/11/curasight-ceo-working-on-accelerated-plan-for-utreat/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se